Effects of UDCA and probiotics on metabolic outcomes in type 2 diabetes patients on metformin: A randomized trial in Bosnia and Herzegovina.
Technol Health CareApr 25, 2026 (epub)
Clinical ResearchEndocrinology
Alma Badnjević-Čengić, Ranko Škrbić, Adna Softić et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effects of probiotics and ursodeoxycholic acid (UDCA) on metabolic outcomes in 90 metformin-treated patients with type 2 diabetes (T2D) over four weeks. The combination of probiotics and UDCA significantly reduced fasting glucose by 1.7 mmol/L, postprandial glucose by 1.3 mmol/L, and HbA1c by 0.49% compared to metformin alone.
Key findings
- Fasting glucose decreased by 1.7 mmol/L in the MPUG group compared to the MG group.
- Postprandial glucose levels dropped by 1.3 mmol/L in the MPUG group.
- HbA1c levels reduced by 0.49% in the MPUG group compared to the MG group.
- Total cholesterol and LDL cholesterol significantly decreased, while HDL increased in the MPUG group.
Why it matters
The study highlights the potential of combining probiotics and UDCA to enhance glycemic and lipid control in patients with type 2 diabetes, suggesting a novel adjunctive therapy to standard metformin treatment.